参考文献
[1] 中华医学会心血管病学分会心力衰竭学组 , 中国医师协会心力衰竭专业委员会 , 中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南 2018[J]. 中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253-3758. 2018.10.004.
[2] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021,42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.
[3] Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy[J]. Eur Heart J, 2019,40(44):3626-3644.DOI: 10.1093/eurheartj/ehy600.
[4] 奥普力农在急性心力衰竭中应用专家共识组 . 奥普力农在急性心力衰竭中应用的专家共识 [J]. 中华急诊医学杂志,2016,25(5):573-576. DOI:10.3760/cma.j.issn.1671-0282. 2016.05.007.
[5] Movsesian M. Novel approaches to targeting PDE3 in cardiovascular disease[J]. Pharmacol Ther, 2016,163:74-81. DOI: 10.1016/j.pharmthera.2016.03.014.
[6] Amsallem E, Kasparian C, Haddour G, et al. PhosphodiesteraseⅢ inhibitors for heart failure[J]. Cochrane Database Syst Rev, 2005(1): D2230. DOI: 10.1002/14651858.CD002230.
[7] Shafiee-Nick R, Afshari AR, Mousavi SH, et al. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases[J]. Biomed Pharmacother, 2017,94:541-556. DOI: 10.1016/j.biopha.2017.07.084.
[8] Kunisawa T, Kasai H , Suda M , et al . Population pharmacokinetics of olprinone in healthy male volunteers[J]. Clin Pharmacol, 2014,6:43-50. DOI: 10.2147/CPAA.S50626.
[9] Lehtonen LA, Antila S, Pentikäinen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents[J]. Clin Pharmacokinet, 2004,43(3):187-203. DOI: 10.2165/00003088-200443030-00003.
[10] Mizushige K, Ueda T, Yukiiri K, et al. Olprinone: a phosphodiesterase Ⅲ inhibitor with positive inotropic and vasodilator effects[J]. Cardiovasc Drug Rev, 2002,20(3):163-174. DOI: 10.1111/j.1527-3466.2002.tb00085.x.
[11] Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial[J]. Circulation, 1985,71(5):963-971. DOI: 10.1161/01.cir.71.5.963.
[12] Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial[J]. JAMA, 2002,287(12):1541-1547. DOI:10.1001/jama.287.12.1541.
[13] Angeloni E, Melina G, Roscitano A, et al. Perioperative administration of enoximone and renal function after cardiac surgery: a propensity-matched analysis[J]. Int J Cardiol, 2013,167(5):1961-1966. DOI: 10.1016/j.ijcard.2012.05.021.
[14] Dobashi S, Watanabe I, Nakanishi R, et al. Comparing the effects of milrinone and olprinone in patients with congestive heart failure[J]. Heart Vessels, 2020,35(6):776-785. DOI: 10.1007/s00380-019-01543-6.
[15] 肖方毅 , 黄伟剑 , 李晟 , 等 . 奥普力农治疗充血性心力衰竭的临床观察 [J]. 心电学杂志,2011,30(6):452-455. DOI: 10.3969/j.issn.1002-1094.2011.06.003.
[16] Endo R, Kurata Y, Notsu T, et al. Stabilization of Kv1.5 channel protein by the inotropic agent olprinone[J]. Eur J Pharmacol, 2015,765:488-494. DOI: 10.1016/j.ejphar.2015.09.013.
[17] Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials[J]. Eur Heart J, 2009,30(24):3015-3026. DOI: 10.1093/eurheartj/ehp338.
[18] Kalogeropoulos AP, Marti CN, Georgiopoulou VV, et al. Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology[J]. J Card Fail, 2014,20(8):593-601. DOI: 10.1016/j.cardfail.2014.05.006.
[19] Gomes C, Terhoch CB, Ayub-Ferreira SM, et al. Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy[J]. Open Heart, 2018,5(2):e000923. DOI: 10.1136/openhrt-2018-000923.
[20] 杨桂棠,韩雅玲,佟铭,等 . 米力农治疗急性心肌梗死并发急性左心衰竭的临床观察 [J]. 心脏杂志 ,2007,19(4):454-456.DOI:10.3969/j.issn.1009-7236.2007.04.024..
[21] Tang X, Liu P, Li R, et al. Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and Meta-Analysis[J]. Basic Clin Pharmacol Toxicol, 2015,117(3):186-194. DOI: 10.1111/bcpt.12385.
[22] Bader FM, Gilbert EM, Mehta NA, et al. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure[J]. Congest Heart Fail, 2010,16(6):265-270. DOI: 10.1111/j.1751-7133.2010.00185.x.
[23] King JB, Shah RU, Sainski-Nguyen A, et al. Effect of inpatient dobutamine versus milrinone on out-of-hospital mortality in patients with acute decompensated heart failure[J]. Pharmacotherapy, 2017,37(6):662-672. DOI: 10.1002/phar.1939.
[24] Kelly J, Cheng J, Malloy R, et al. Comparison of positive inotropic agents in the management of acute decompensated heart failure[J]. J Cardiovasc Pharmacol, 2020,75(5):455-459. DOI: 10.1097/FJC.0000000000000811.
[25] Constantinescu AA, Caliskan K, Manintveld OC, et al. Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis[J]. Eur J Heart Fail, 2014,16(4):435-443. DOI: 10.1002/ejhf.39.
[26] Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure[J]. Circ Heart Fail, 2015,8(5):880-886. DOI: 10.1161/CIRCHEARTFAILURE.114.001778.
[27] Lee EC, McNitt S, Martens J, et al. Long-term milrinone therapy as a bridge to heart transplantation: safety, efficacy, and predictors of failure[J]. Int J Cardiol, 2020,313:83-88. DOI: 10.1016/j.ijcard.2020.04.055.
[28] Ren YS, Li LF, Peng T, et al. The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis[J]. BMC Cardiovasc Disord, 2020,20(1):328. DOI: 10.1186/s12872-020-01598-8.
[29] El-Khuffash A, McNamara PJ, Breatnach C, et al. The use of milrinone in neonates with persistent pulmonary hypertension of the newborn-a randomised controlled trial pilot study (MINT 1): study protocol and review of literature[J]. Matern Health Neonatol Perinatol, 2018,4:24. DOI: 10.1186/s40748-018-0093-1.
[30] Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?[J]. Curr Opin Crit Care, 2019,25(4):384-390. DOI: 10.1097/MCC.0000000000000632.
[31] 国家卫生计生委合理用药专家委员会 , 中国药师协会 . 心力衰竭合理用药指南 ( 第 2 版 )[J]. 中国医学前沿杂志(电子版),2019,11(7):1-78. DOI: 10.12037/YXQY.2019.07-01.